Cargando…

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin

The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tura, Andrea, Farngren, Johan, Schweizer, Anja, Foley, James E., Pacini, Giovanni, Ahrén, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637474/ https://www.ncbi.nlm.nih.gov/pubmed/26587020 http://dx.doi.org/10.1155/2015/484231

Ejemplares similares

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Relative contributions of preprandial and postprandial glucose exposures, glycemic variability, and non-glycemic factors to HbA(1c) in individuals with and without diabetes
por: Færch, Kristine, et al.
Publicado: (2018)

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
por: Schweizer, Anja, et al.
Publicado: (2012)

Glucose effectiveness: Lessons from studies on insulin‐independent glucose clearance in mice
por: Ahrén, Bo, et al.
Publicado: (2020)

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes
por: Blüher, Matthias, et al.
Publicado: (2014)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
por: Lukashevich, Valentina, et al.
Publicado: (2013)

Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test
por: Morettini, Micaela, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 and glucose‐dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice
por: Pacini, Giovanni, et al.
Publicado: (2017)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors
por: Morettini, Micaela, et al.
Publicado: (2021)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
por: Pacini, Giovanni, et al.
Publicado: (2022)

Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice
por: Ovlund, Tina, et al.
Publicado: (2021)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
por: Halimi, Serge, et al.
Publicado: (2008)

Preprandial ghrelin is not affected by macronutrient intake, energy intake or energy expenditure
por: Paul, David R, et al.
Publicado: (2005)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes
por: Li, Feng-fei, et al.
Publicado: (2017)

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
por: Kothny, Wolfgang, et al.
Publicado: (2015)

Flash Glucose Monitoring to Assess Glycemic Control and Variability in Hemodialysis Patients: The GIOTTO Study
por: Mambelli, Emanuele, et al.
Publicado: (2021)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
por: Schweizer, Anja, et al.
Publicado: (2011)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
por: Batule, Sol, et al.
Publicado: (2022)

Impact of glucose dosing regimens on modeling of glucose tolerance and β‐cell function by intravenous glucose tolerance test in diet‐induced obese mice
por: Omar, Bilal A., et al.
Publicado: (2014)

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus
por: Evans, Marc, et al.
Publicado: (2016)

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
por: Schweizer, Anja, et al.
Publicado: (2013)

Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management
por: Dejager, Sylvie, et al.
Publicado: (2011)

Measurement of preprandial and postprandial urine calcium to creatinine ratios in male Miniature Schnauzers with and without urolithiasis
por: Carr, Susan V., et al.
Publicado: (2020)

Differential Development of Glucose Intolerance and Pancreatic Islet Adaptation in Multiple Diet Induced Obesity Models
por: Omar, Bilal, et al.
Publicado: (2012)

Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments
por: Tura, Andrea, et al.
Publicado: (2022)

Efficacy Comparison of Preprandial and Postprandial Prandilin 25 Administration in Patients with Newly Diagnosed Type 2 Diabetes Using a Continuous Glucose Monitoring System
por: Luo, Yong, et al.
Publicado: (2019)

Glycemic variability is complex - is glucose complexity variable?
por: van Hooijdonk, Roosmarijn TM, et al.
Publicado: (2012)

Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients
por: Göbl, Christian, et al.
Publicado: (2022)

Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
por: Ito, Hiroyuki, et al.
Publicado: (2013)

Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin
por: Okajima, Fumitaka, et al.
Publicado: (2017)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

Glucose concentrations after insulin‐induced hypoglycemia and glycemic variability in healthy and diabetic cats
por: Zini, Eric, et al.
Publicado: (2018)

Glucose Effectiveness from Short Insulin-Modified IVGTT and Its Application to the Study of Women with Previous Gestational Diabetes Mellitus
por: Morettini, Micaela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9b7r5n0uf2ru80ht181tns6v8c